- Home
- ENVB vs REVB Comparison
ENVB vs REVB Comparison
Compare ENVB & REVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENVB
- REVB
- Stock Information
- Founded
- ENVB 1994
- REVB 2020
- Country
- ENVB United States
- REVB United States
- Employees
- ENVB N/A
- REVB N/A
- Industry
- ENVB Biotechnology: Pharmaceutical Preparations
- REVB Biotechnology: Pharmaceutical Preparations
- Sector
- ENVB Health Care
- REVB Health Care
- Exchange
- ENVB Nasdaq
- REVB Nasdaq
- Market Cap
- ENVB 3.0M
- REVB 3.4M
- IPO Year
- ENVB N/A
- REVB N/A
- Fundamental
- Price
- ENVB $6.70
- REVB $1.28
- Analyst Decision
- ENVB Strong Buy
- REVB
- Analyst Count
- ENVB 1
- REVB 0
- Target Price
- ENVB $10.00
- REVB N/A
- AVG Volume (30 Days)
- ENVB 63.7K
- REVB 191.2K
- Earning Date
- ENVB 11-13-2025
- REVB 11-07-2025
- Dividend Yield
- ENVB N/A
- REVB N/A
- EPS Growth
- ENVB N/A
- REVB N/A
- EPS
- ENVB N/A
- REVB N/A
- Revenue
- ENVB N/A
- REVB N/A
- Revenue This Year
- ENVB N/A
- REVB N/A
- Revenue Next Year
- ENVB N/A
- REVB N/A
- P/E Ratio
- ENVB N/A
- REVB N/A
- Revenue Growth
- ENVB N/A
- REVB N/A
- 52 Week Low
- ENVB $6.63
- REVB $1.15
- 52 Week High
- ENVB $99.00
- REVB $60.48
- Technical
- Relative Strength Index (RSI)
- ENVB 89.48
- REVB 38.23
- Support Level
- ENVB $0.59
- REVB $1.23
- Resistance Level
- ENVB $7.51
- REVB $1.38
- Average True Range (ATR)
- ENVB 0.17
- REVB 0.09
- MACD
- ENVB 0.63
- REVB 0.03
- Stochastic Oscillator
- ENVB 88.33
- REVB 38.24
About ENVB Enveric Biosciences Inc.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).